NASDAQ:RGNX REGENXBIO (RGNX) Stock Forecast, Price & News $18.56 +1.33 (+7.72%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$17.05▼$18.8250-Day Range$17.23▼$21.7152-Week Range$17.02▼$35.73Volume430,858 shsAverage Volume417,700 shsMarket Capitalization$806.80 millionP/E RatioN/ADividend YieldN/APrice Target$40.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability REGENXBIO MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside115.5% Upside$40.00 Price TargetShort InterestBearish12.32% of Float Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.81Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.31) to ($2.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector997th out of 1,980 stocksBiological Products, Except Diagnostic Industry151st out of 330 stocks 3.4 Analyst's Opinion Consensus RatingREGENXBIO has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.00, REGENXBIO has a forecasted upside of 115.5% from its current price of $18.56.Amount of Analyst CoverageREGENXBIO has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.32% of the float of REGENXBIO has been sold short.Short Interest Ratio / Days to CoverREGENXBIO has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in REGENXBIO has recently increased by 2.53%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldREGENXBIO does not currently pay a dividend.Dividend GrowthREGENXBIO does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreREGENXBIO has received a 71.89% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for REGENXBIO is -0.82. Previous Next 2.7 News and Social Media Coverage News SentimentREGENXBIO has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for REGENXBIO this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added REGENXBIO to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, REGENXBIO insiders have not sold or bought any company stock.Percentage Held by Insiders12.70% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.21% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for REGENXBIO are expected to grow in the coming year, from ($4.31) to ($2.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of REGENXBIO is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of REGENXBIO is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioREGENXBIO has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About REGENXBIO (NASDAQ:RGNX) StockREGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.Read More Receive RGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address RGNX Stock News HeadlinesJune 1, 2023 | finance.yahoo.comREGENXBIO Announces Presentation at the Jefferies Global Healthcare ConferenceJune 1, 2023 | americanbankingnews.comREGENXBIO (NASDAQ:RGNX) versus Vaxcyte (NASDAQ:PCVX) Critical SurveyJune 2, 2023 | Legacy Research (Affiliate) (Ad)The “Amazon Secret Royalty Program” Can Help Anyone Retire Like RoyaltyA unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.May 27, 2023 | americanbankingnews.comREGENXBIO (NASDAQ:RGNX) Shares Down 7.5% May 23, 2023 | seekingalpha.comRegenxbio's gene therapy for Hunter syndrome gets FDA regenerative medicine statusMay 23, 2023 | finance.yahoo.comREGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter SyndromeMay 22, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on REGENXBIO (NASDAQ:RGNX)May 22, 2023 | americanbankingnews.comREGENXBIO Inc. (NASDAQ:RGNX) Receives $40.00 Consensus Target Price from AnalystsJune 2, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 17, 2023 | americanbankingnews.comREGENXBIO (NASDAQ:RGNX) Shares Up 8.8%May 16, 2023 | finance.yahoo.comREGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical PortfolioMay 12, 2023 | msn.comRegenxbio: Buy, High-Potential Stock Stagnant Due To No Near-Term CatalystsMay 12, 2023 | msn.comRegenxbio's Return On Capital Employed InsightsMay 10, 2023 | markets.businessinsider.comAnalyst Expectations for Regenxbio's FutureMay 10, 2023 | msn.comMorgan Stanley Maintains Regenxbio (RGNX) Overweight RecommendationMay 8, 2023 | americanbankingnews.comREGENXBIO (NASDAQ:RGNX) PT Lowered to $55.00May 7, 2023 | americanbankingnews.comREGENXBIO (NASDAQ:RGNX) Stock Price Down 5.8% Following Analyst DowngradeMay 6, 2023 | americanbankingnews.comREGENXBIO (NASDAQ:RGNX) Shares Gap Down After Earnings MissMay 5, 2023 | americanbankingnews.comREGENXBIO (NASDAQ:RGNX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPSMay 3, 2023 | finance.yahoo.comREGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational HighlightsMay 2, 2023 | finance.yahoo.comREGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual MeetingMay 1, 2023 | americanbankingnews.comREGENXBIO (RGNX) Scheduled to Post Quarterly Earnings on WednesdayApril 26, 2023 | finance.yahoo.comREGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational HighlightsApril 25, 2023 | americanbankingnews.comREGENXBIO Inc. (NASDAQ:RGNX) Receives $40.86 Consensus Price Target from AnalystsApril 18, 2023 | finance.yahoo.comREGENXBIO Announces Presentation at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 15, 2023 | americanbankingnews.comHead-To-Head Survey: Vaxart (NASDAQ:VXRT) versus REGENXBIO (NASDAQ:RGNX)April 12, 2023 | markets.businessinsider.comREGENXBIO: FDA Grants Fast Track Designation For RGX-202See More Headlines RGNX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGNX Company Calendar Last Earnings5/03/2023Today6/02/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RGNX CUSIPN/A CIK1590877 Webwww.regenxbio.com Phone(240) 552-8181FaxN/AEmployees372Year FoundedN/APrice Target and Rating Average Stock Price Forecast$40.00 High Stock Price Forecast$61.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+115.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($6.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-280,320,000.00 Net Margins-246.50% Pretax Margin-246.54% Return on Equity-49.69% Return on Assets-31.63% Debt Debt-to-Equity RatioN/A Current Ratio3.46 Quick Ratio3.46 Sales & Book Value Annual Sales$112.72 million Price / Sales7.16 Cash FlowN/A Price / Cash FlowN/A Book Value$10.70 per share Price / Book1.73Miscellaneous Outstanding Shares43,470,000Free Float37,946,000Market Cap$806.80 million OptionableOptionable Beta1.08 Key ExecutivesKenneth T. MillsPresident, Chief Executive Officer & DirectorCurran M. SimpsonChief Operating OfficerVit VasistaChief Financial Officer & Senior Vice PresidentJerome W. JacksonVice President-Information TechnologyOlivier DanosChief Scientific Officer & Senior Vice PresidentKey CompetitorsImmaticsNASDAQ:IMTXAnavex Life SciencesNASDAQ:AVXLAllogene TherapeuticsNASDAQ:ALLOValnevaNASDAQ:VALNTwist BioscienceNASDAQ:TWSTView All CompetitorsInsiders & InstitutionsRoyce & Associates LPBought 100,871 shares on 5/23/2023Ownership: 0.420%Ameriprise Financial Inc.Bought 74,523 shares on 5/22/2023Ownership: 0.675%JPMorgan Chase & Co.Bought 211,146 shares on 5/18/2023Ownership: 9.215%New York State Common Retirement FundSold 4,307 shares on 5/18/2023Ownership: 0.056%Thrivent Financial for LutheransSold 1,309 shares on 5/17/2023Ownership: 0.086%View All Insider TransactionsView All Institutional Transactions RGNX Stock - Frequently Asked Questions Should I buy or sell REGENXBIO stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RGNX shares. View RGNX analyst ratings or view top-rated stocks. What is REGENXBIO's stock price forecast for 2023? 7 Wall Street research analysts have issued twelve-month target prices for REGENXBIO's stock. Their RGNX share price forecasts range from $14.00 to $61.00. On average, they expect the company's stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 115.5% from the stock's current price. View analysts price targets for RGNX or view top-rated stocks among Wall Street analysts. How have RGNX shares performed in 2023? REGENXBIO's stock was trading at $22.68 at the start of the year. Since then, RGNX stock has decreased by 18.2% and is now trading at $18.56. View the best growth stocks for 2023 here. When is REGENXBIO's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our RGNX earnings forecast. How were REGENXBIO's earnings last quarter? REGENXBIO Inc. (NASDAQ:RGNX) announced its earnings results on Wednesday, May, 3rd. The biotechnology company reported ($1.53) earnings per share for the quarter, missing analysts' consensus estimates of ($1.52) by $0.01. The biotechnology company had revenue of $19.10 million for the quarter, compared to analyst estimates of $31.29 million. REGENXBIO had a negative net margin of 246.50% and a negative trailing twelve-month return on equity of 49.69%. REGENXBIO's quarterly revenue was down 14.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.62) earnings per share. What ETFs hold REGENXBIO's stock? ETFs with the largest weight of REGENXBIO (NASDAQ:RGNX) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), WisdomTree BioRevolution Fund (WDNA), ETC 6 Meridian Small Cap Equity ETF (SIXS), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco S&P SmallCap Health Care ETF (PSCH) and Invesco Raymond James SB-1 Equity ETF (RYJ). What is Ken Mills' approval rating as REGENXBIO's CEO? 3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees. What other stocks do shareholders of REGENXBIO own? Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ). What is REGENXBIO's stock symbol? REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX." Who are REGENXBIO's major shareholders? REGENXBIO's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (18.50%), JPMorgan Chase & Co. (9.21%), State Street Corp (5.94%), Dimensional Fund Advisors LP (3.53%), Geode Capital Management LLC (1.75%) and First Manhattan CO. LLC. (1.03%). Insiders that own company stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust. View institutional ownership trends. How do I buy shares of REGENXBIO? Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is REGENXBIO's stock price today? One share of RGNX stock can currently be purchased for approximately $18.56. How much money does REGENXBIO make? REGENXBIO (NASDAQ:RGNX) has a market capitalization of $806.80 million and generates $112.72 million in revenue each year. The biotechnology company earns $-280,320,000.00 in net income (profit) each year or ($6.24) on an earnings per share basis. How many employees does REGENXBIO have? The company employs 372 workers across the globe. How can I contact REGENXBIO? REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The official website for the company is www.regenxbio.com. The biotechnology company can be reached via phone at (240) 552-8181 or via email at ir@regenxbio.com. This page (NASDAQ:RGNX) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.